Nevertheless, it also implies a potential increased sensitivity to SF3B1 modulators, presenting a novel precision medicine strategy for more efficacious therapeutic interventions in addressing these exceptionally chemoresistant cancers. The gene discussed is SF3B1; the disease is cancer.